Ron Renaud's Fourth Bet: Obesity Drugs

Ron Renaud has a habit of selling companies at exactly the right moment. Idenix to Merck in 2014, Translate Bio to Sanofi in 2021, Cerevel Therapeutics to AbbVie in 2024 for $8.7 billion. Three exits in a decade, each one timed with eerie precision to the ascending slope of a platform shift — antivirals, mRNA, neuroscience. Now Renaud is back, and the bet is obesity.

Kailera Therapeutics filed for a U.S. IPO on March 27, 2026, applying to list on Nasdaq under the ticker KLRA, according to Reuters. The filing size is listed at up to $100 million — a placeholder figure that typically adjusts upward before the actual offering. The Waltham, Massachusetts-based company has already raised $1 billion pre-IPO: a $400 million Series A in October 2024 co-led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments, according to Kailera, followed by a $600 million Series B in October 2025 led by Bain Capital Private Equity with participation from QIA, Royalty Pharma, Citadel/Surveyor Capital, T. Rowe Price, and others, according to Kailera. That's a meaningful war chest for a company that is essentially licensing its way into the most contested drug market in decades.

The drug is called ribupatide — formerly HRS9531 — a weekly injectable dual GLP-1 and GIP receptor agonist developed by Jiangsu Hengrui Pharmaceuticals in China. Kailera acquired exclusive global rights outside greater China in May 2024 for $110 million upfront plus near-term payments, a 19.9 percent equity stake in Kailera, and up to approximately $5.925 billion in development and sales milestones, according to Nature Portfolio. That's a structure that lets Hengrui capture Chinese market value while Kailera runs the global show. Hengrui has already submitted a marketing authorization application to China's National Medical Products Administration for chronic weight management, which was accepted.

The clinical data is where the story gets interesting. In a Phase 3 trial conducted in China (HRS9531-301, NCT06396429), 567 adults with obesity received weekly injections of 2 mg, 4 mg, or 6 mg of HRS9531 for 48 weeks. Participants on the 6 mg dose achieved a mean weight loss of 19.2 percent, with 88 percent losing at least 5 percent of body weight and 44.4 percent losing 20 percent or more, according to Kailera. The trial met both co-primary endpoints. In an earlier Phase 2 trial, the 8 mg dose achieved 23.6 percent mean weight loss at 36 weeks, with no observed plateau in either trial, suggesting the drug may not have hit its ceiling yet.

But the timing of this filing is the real narrative. Two weeks before Kailera's IPO paperwork landed, Novo Nordisk acknowledged that its CagriSema — a cagrilintide-semaglutide combination — achieved only 23 percent weight loss in a head-to-head trial against tirzepatide, which posted 25.5 percent, Reuters reported. Novo's drug underperformed expectations that had been built on earlier-phase signals. Lilly won that round, and the market reacted accordingly. The broader GLP-1 field had been watching CagriSema as a potential best-in-class entrant; its stumble recalibrated everyone's sense of where the competitive bar actually sits.

Kailera is walking into that opening. Its global Phase 3 program — called KaiNETIC — is already enrolling. KaiNETIC-1 targets 1,800 participants without type 2 diabetes; KaiNETIC-2 targets 1,700 with type 2 diabetes; and KaiNETIC-3 is the one that matters for competitive positioning: 1,200 participants randomized to ribupatide doses of 8 mg or 10 mg, placebo, or open-label semaglutide 2.4 mg, according to Kailera. More than 2,500 trial participants have been dosed with ribupatide with treatment extending out to 52 weeks, providing a safety database that the FDA will scrutinize carefully.

Tirzepatide's superiority over semaglutide was already established in SURMOUNT-5, a 72-week head-to-head trial where tirzepatide achieved 20.2 percent weight loss versus 13.7 percent for semaglutide, according to results published in the New England Journal of Medicine. CagriSema was supposed to reclaim Novo's advantage. It didn't.

The roster of investors backing this effort is notable. Bain Capital appears twice — as co-lead of the Series A and lead of the Series B — a level of repeat commitment that suggests conviction beyond diversification. John Milligan, who spent three decades at Gilead Sciences and oversaw its transformation into a global pharmaceutical leader, is board chair. J.P. Morgan, Jefferies, Leerink Partners, TD Cowen, Evercore ISI, and William Blair are among the underwriters for the IPO, according to Reuters.

There are real risks worth naming. The Phase 3 data so far comes from a Chinese trial population, and global Phase 3 results have been known to diverge from single-region data — in either direction. Kailera is also simultaneously running an oral formulation of ribupatide through Phase 2, which adds complexity to manufacturing and supply chain at exactly the moment it will need to scale. And the $100 million IPO figure, while large in absolute terms, suggests the company expects to raise again — the pre-IPO burn rate and Phase 3 costs will demand it.

The GLP-1 market is no longer a two-horse race with a wide-open tail. Lilly and Novo have first-mover advantage, manufacturing scale, and established payer relationships. But obesity is a large enough market — and the unmet need for better tolerated, more effective, more convenient options remains acute enough — that third and fourth players can coexist profitably. The question is whether ribupatide can differentiate clearly enough on efficacy, safety, or convenience to capture meaningful share rather than simply existing in the category.

Renaud has timed three exits to platform shifts. This time he's not selling — he's buying a shot at something bigger. The KaiNETIC-3 data will tell us whether that bet has a future.